News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Revenue from operations up 26% to Rs. 768 crores
Periodic community awareness program through Aster’s DM Healthcare’s visual media and social media platforms and implementing TB control activity through Aster Pharmacies across South India
The move will add new global talent to Cytel’s Strategic Consulting group
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Subscribe To Our Newsletter & Stay Updated
